MicroRNAs (miRNAs) regulate many genes critical for tumorigenesis. We profiled miRNAs from 11 normal breast tissues, 17 non-invasive, 151 invasive breast carcinomas, and 6 cell lines by in-house-developed barcoded Solexa sequencing. miRNAs were organized in genomic clusters representing promoter controlled miRNA expression and sequence families representing seed-sequence-dependent miRNA-target regulation. Unsupervised clustering of samples by miRNA sequence families best reflected the clustering based on mRNA expression available for this sample set. Clustering and comparative analysis of miRNA read frequencies showed that normal breast samples were separated from most non-invasive ductal carcinoma in situ and invasive carcinomas due to increased miR-21, the most abundant miRNA in carcinomas, and multiple decreased miRNA families (including mir-98/let-7), with most miRNA changes apparent already in the non-invasive carcinomas. Patients that went on to develop metastasis demonstrated increased expression of mir-423. Triple negative breast carcinomas were most distinct from other tumor subtypes due to upregulation of the mir-17~92 cluster. Furthermore, absolute miRNA levels between normal breast and carcinomas did not reveal any significant differences. Finally we did not identify nucleotide variations expected for classical tumor suppressor function associated with the seed region of tumor-downregulated miRNAs. However, we discovered two rare polymorphic nucleotide variations in miR-181a (T19G) and miR-185 (T16G). The differentiation of tumor subtypes and prediction of metastasis based on miRNA levels is statistically possible, but is not driven by deregulation of abundant miRNAs, implicating far fewer miRNAs in oncogenic processes than previously suggested. 138 9 miRNA sequence and expression analysis in breast tumors
Introduction
Breast cancer is a heterogeneous disease involving various oncogenic pathways and/or genetic alterations. Even though prognostic mRNA expression signatures have been defined for some invasive breast carcinomas (1, 2) , the underlying pathways that regulate breast cancer aggressiveness are poorly understood. miRNAs are 19-23 nucleotide (nt) RNAs that regulate gene expression (3, 4, 5) . Similarly to oncogenes, such as HER2, whose over-expression defines a subset of breast tumors, miRNAs have also been suggested to act as oncogenes (or tumor suppressors) contributing to distinct tumor characteristics (6, 7, 8, 9) . Some miRNAs are located in genomic regions that show copy number alterations (10) and their levels can be dramatically deregulated in tumors, e.g. up-regulation of mir-21 (reviewed in (11) ), mir-17-92 cluster (reviewed in (12) ), mir-26a (13) , and down-regulation of let-7 family members (reviewed in (14) ). miRNAs have been shown to control various key processes in tumorigenesis, such as tumor initiation (13) , metastasis (15, 16) , inflammation (17) , and differentiation (18) in cell lines and animal models. Components of the miRNA biogenesis pathway have been implicated in tumorigenesis, suggesting that miRNA levels are less abundant in tumors (19, 20, 21) . For example, DICER1 was found to function as a haplo-insufficient tumor suppressor (20, 21) ; 27% of various tumors were suggested to have a hemizygous deletion of the gene that encodes DICER1 (20) . Furthermore, miRNA profiling in a variety of tissues and cancers has not only identified cell-type-specific and cancer-deregulated miRNAs (19, 22) , but also profiles that correlate with prognosis (23) . Since 2005, when miRNA deregulation was described in breast tumors (24) , over 400 studies have been published regarding changes in miRNA levels, their regulation and role in breast cancer (reviewed in (25) ). Most of these studies were conducted for a specified subset of miRNAs using microarrays or RT-PCR, and did not capture miRNA abundance, sequence variation and/or allow quantification of miRNA levels in breast tumors and normal tissue. Studies investigating the role of specific miRNAs in metastasis were conducted in cell lines and animal models, and were supported by small patient cohorts. For example, over-expression/ knockdown of several miRNAs, including miR-10b, miR-9, miR-31, miR-126 and miR-335, was shown to play a role in metastasis (15, 26, 27, 16) . However, correlation between these miRNAs and metastasis was not identified in large clinical studies (28, 29) . Here, we surveyed by barcoded Solexa-sequencing 185 breast specimens, including 11 normal breast, 17 ductal carcinoma in situ (DCIS), 151 invasive carcinomas (including 128 invasive ductal carcinomas (IDC)) and 6 ductal cell lines and obtained expression levels based on the number of sequence reads. This approach not only provided the fold-differences, but also characterized miRNA abundance and nucleotide variation, accommodating a large number of clinical samples to address inter-patient variation in a cost-effective manner. We performed unsupervised clustering to assess if miRNAs organized in genomic clusters or sequence families could resolve breast cancer types, as assessed by immunohistochemistry (IHC) i.e. estrogen receptor (ER), progesterone receptor (PR) and HER2 status, and molecular subtypes based on mRNA profiles. By comparing HER2-positive non-invasive (DCIS) and invasive breast carcinomas we identified miRNAs with altered levels in tumor invasion. By comparing breast tumor types with different IHC characteristics we identified miRNAs that are unique to triple negative breast carcinomas (TNBC), lacking expression for ER, PR and HER2. 97 out of 151 invasive breast carcinoma patients had clinical follow-up records available, allowing us to evaluate the role of miRNAs as prognostic markers. 140 9 miRNA sequence and expression analysis in breast tumors miRNA profiles in normal and tumor specimens miRNA profiles of a sample can be presented as relative percent (%) miRNA read frequencies (rf) by dividing miRNA read counts by total miRNA reads per library. Alternatively, miRNA profiles can be condensed either by assigning individual miRNA and miRNA star reads to their originating miRNA genomic clusters or to sequence families (22) (denoted clustermir and sf-miR respectively, and listing number of cluster/family members in parenthesis (Suppl . Table S4 ). Both miRNA grouping approaches reduce the complexity of the data. The genomic cluster profiles represent promoter-controlled miRNA expression, while the sequence families characterize seed-sequence-dependent miRNA target regulation. For sample comparison, we required > 5,000 total miRNA sequence reads per replicate merged library, resulting in inclusion of 179 samples (from 183 sequenced) and 6 cell lines. We conducted unsupervised hierarchical clustering for 179 clinical specimens using individual miRNAs, precursor clusters and sequence families expressed at 85% of the total miRNA reads in at least one sample (Figure 1 and Suppl. Figure S2 ). To enhance visualization of changes in miRNA expression, miRNA rf was transformed by normalization across each miRNA. Normal breast specimens clustered together, close to a small group of ER and HER2 positive tumors characterized by lower expression of sf-miR-21(1) and higher expression of sf-miR-22(1) compared to the remainder of tumor specimens. Some DCIS specimens also clustered together, breaking up groups of invasive tumor samples, suggesting that DCIS specimens accumulate changes in miRNA expression early in the tumorigenic process. Invasive tumor samples positive for one or more IHC marker clustered together while TNBCs emerged as several groups distinct from the other tumors. Specimens did not cluster according to other pathological and clinical characteristics, including presence of distant metastasis and overall survival. To understand miRNA expression in the context of tissue heterogeneity, we compared the six ductal cell lines to human samples to identify miRNAs expressed in tissues, but not ductal cell lines, likely contributed by other cell types. We visualized miRNA abundance in normal, DCIS and IDC IHC types. We selected four representative samples from each IHC category that demonstrated miRNA expression closest to the average expression for each category, representing miRNAs expressed at 85% of the total miRNA reads in at least one sample or cell line (Figure 2 ). We identified miRNAs present at similar levels in cell lines and tumors that may be involved in tumorigenic processes, and miRNAs absent from cell lines that are likely expressed by other cell types, such as cluster-mir-126(1) (cardiovascular system), cluster-mir-144(2) (hematopoietic system), cluster-mir-143(2) (adipose tissue), and clustermir-142 (hematopoietic system). The most abundant miRNA clusters across all specimens were cluster-miR-21(1), cluster-mir-98(13) and cluster-mir-23a (6) . Clustering of 179 specimens based on miRNAs (using 98% of miRNAs expressed in each specimen) and clustering of 161 of these specimens according to their mRNA profiles (using the same number of genes as miRNAs) is depicted in Figure 3 . mRNA clustering appeared to be driven by HER2 status, whereas miRNA clustering is weakly correlated with TNBC. Three TNBC groups emerged by clustering miRNA profiles, one of which included mostly special histological types; the other two groups demonstrated differential miRNA levels, including sf-miR-181a-1(6), but not distinct patient characteristics or outcome. mRNA profiles better separated HER2 positive samples, suggesting that the HER2 pathway is not related to miRNA expression changes. We used the EdgeR package (32) to identify individual mature miRNAs, miRNA genomic clusters and miRNA sequence families differentially represented between normal, DCIS and invasive tumor samples. We included miRNAs that were amongst the top 85% sequence reads in at least one sample, to limit our analysis to regulatory important miRNAs and potential biomarkers. The EdgeR algorithm compensates for the difference in sequence reads between samples, as well as the different number of samples within the categories compared. First, we compared normal samples to HER2 positive DCIS (non-invasive) and IDC samples. Sf-miR-21 (1) is the only abundant (> 1% rf) up-regulated miRNA in IDC compared to normal breast with a p-value <0.001 ( Figure 4A , Table 1 and Table S6 ). Cluster-mir-98(13) members (sf-125a(3), sf-99a (3)), sf-miR-22(1), and cluster-mir-143(2) members (sf-miR-145(1), sfmiR-143*(1) (sf-miR-143(1) was reduced but not statistically significant) were examples of abundant miRNAs in normal breast reduced in invasive carcinomas, either representing miRNA sequence and expression analysis in breast tumors miRNAs down-regulated in tumors or miRNAs expressed in cell types other than the ductal cell giving rise to the tumors. miRNAs present both in ductal cell lines and tumors likely represent tumor down-regulated miRNAs (cluster-mir-98/let-7(13) and cluster-mir-22(1)). miRNAs absent in ductal cell lines may be expressed in other cell types reflecting differences in tissue composition (i.e. adipose specific cluster-mir-143/145 is likely related to the presence of adipose tissue in the biopsies). To identify miRNAs altered in tumor invasion, we compared HER2 positive DCIS and IDC specimens. Cluster-mir-142(1) members (sf-miR-142-3p(1) and sf-miR-142-5p(1)), were over-represented in HER2 positive IDC compared to DCIS. Given that cluster-mir-142(1) is hematopoietic lineage specific, this may reflect a change in tissue composition, rather than a change in miRNA expression within the ductal cancer cells. We then employed EdgeR to determine whether mature miRNA/sequence family/genomic cluster levels correlated with IHC or special histological characteristics ( Figure 4B and Suppl. Table S5 ). Differences in miRNA representation between IHC subtypes involved several less abundant miRNAs. TNBC showed the largest number of changes in low abundant miRNAs. Cluster-mir-17(12) member sf-miR-19a(3) (present in ductal cell lines), as well as less abundant sf-miR-205(1) and sf-miR-146a(2) (lower-represented in ductal cell lines), were higher expressed in TNBC compared to either HER2 or ER positive tumors. Special histological TNBCs (atypical medullary, metaplastic, adenoid cystic and apocrine breast carcinomas) were differentiated from IDC TNBCs by lowly abundant sf-miR-224(1), absent from some ductal cell lines. Some miRNA genomic clusters (cluster-mir-224(2), cluster-mir-181c(2), cluster-mir-10a(1) in isolated specimens exhibited a larger degree of up-regulation compared to most samples, suggesting putative oncogenic roles for these miRNAs. Sequence-specific biases in the efficiency of cDNA library preparation can distort the representation of individual miRNAs by number of sequence read counts in a reproducible manner; however, these biases would not affect the comparisons between different sample groups. We used an equimolar pool of synthetic miRNAs to address possible biases in our method (Hafner, unpublished data) . This analysis did not show an over-representation above the median rf >5-fold for any of the miRNAs meeting our cutoff for analysis, but it did show under-representation >5-fold for miR-193a, miR-193b, miR-26b, and miR-30b. Among the >5-fold under-represented miRNAs was miR-31, previously implicated in metastasis, which did not meet our analysis cutoff. miRNA sequence and expression analysis in breast tumors miRNAs as prognostic markers within TNBC and HER2 positive tumors We evaluated the prognostic capacity of miRNAs on 48 TNBC and 49 HER2 positive patients, for which clinical follow-up information (distant metastasis free survival and overall survival) was available with a mean follow-up of 5.6 years. Lowly represented (<1% rf) clustermir-423(2) members (sf-miR-423-3p(1) and sf-miR-423-5p(1)), and cluster-mir-375(1)/sfmiR-375(1) were more abundant in patients that went on to develop metastasis, while clustermir-184(1)/sf-miR-184(1) was less abundant (p values <0.001) ( Figure 4C , Table S6 ). KaplanMeier analyses supported the findings for cluster-mir-423(2) (p=0.013) and sf-miR-184(1)/ miRNA sequence and expression analysis in breast tumors cluster-mir-184(1) (p=0.041) in HER2 positive patients (Suppl. Figure 3 ). Univariate and multivariate Cox regression indicated that cluster-mir-423(1) is an independent predictor of outcome in the presence of other well known clinical parameters (tumor size, grade and lymph node status; data not shown). However, this should be interpreted with caution since these p values do not account for multiple testing.
Analysis of miRNA sequence variation in clinical specimens and cell lines miRNAs have been proposed to act as tumor suppressors or oncogenes, yet somatic mutations in cancer patients have not been detected to support this proposal. For identification of nucleotide variations relative to the reference human genome, we required a minimum of 10 varied sequence reads covering a given position per sample, with > 25% variation frequency. This cutoff guaranteed that 98% of the identified variations were not random events, and sequence mapping problems rather than sequencing errors were responsible for scoring variations, based on analysis of deep-sequencing data from a pool of 770 synthetic miRNAs (Hafner, unpublished data). We identified 248 distinct nucleotide variations located within 150 miRNA precursor sequences. We masked the last two positions of the predominant mature sequence read to exclude frequent instances of untemplated 3' terminal addition, filtering out 64 variations (59 of which represented changes into A or U) (Suppl. Table 6 ). 35 variations were located within the mature or star miRNA; none of these variations were detected in abundant miRNAs (>1% rf). 149 variations were located elsewhere in the miRNA precursor, predominantly representing G to C changes. We focused on further analyzing the 35 variations within the mature and star miRNAs. RNA sequence variations could represent RNA editing events (including deamination, polyuridylation, polyadenylation), SNPs or somatic mutations. The most common variations observed in the mature and star miRNA sequences among all samples were A to G, likely representing A to I RNA editing by dsRNA-specific adenosine deaminases (33, 22, 34, 35) . This was further supported by a well-represented unimodal distribution of the nucleotide variation frequency for miRNAs previously reported to be edited in normal tissues, miR-376a and miR-376c. miR-625 (detected in 17 samples), miR-497* (n=9) and miR-381 (member of the same genomic cluster miR-376 belongs to; n=17) could represent editing events not previously reported (Suppl. Figure 4 , and 5). Deamination events were not noted in cell lines. We detected two known SNPs (SNPdb version 131) in miR-196a-2* and miR-146a (present at <85% of all miRNA reads) which have been studied in the context of breast cancer risk (rs11614913 and rs2910164) (36, 37, 38, 39) . rs2910164 (C5G) was detected in five carcinomas, while rs11614913 (C18T) was detected in 39 specimens including one normal breast specimen and three cell lines. We identified 10 nucleotide variations that are likely new SNPs, based on the tri-modal distribution of the variation frequency. Two of these variations were identified in miRNAs present at 85% of all miRNA reads in at least one sample: miR-181a (T19G) observed in 10 carcinomas and miR-185 (T16G) observed in three carcinomas. There was no evidence for somatic mutations in mature miRNAs detected solely in tumors.
C. miRNA sf that predict metastasis in IDC, also broken down by HER2 positive and TNBC patients.
9 miRNA sequence and expression analysis in breast tumors

Discussion
The first study on miRNA deregulation in breast cancer by Iorio et al. used microarrays to compare a variety of breast carcinomas (n=76) to normal (n=10) breast tissue (24), identifying 17 up-regulated and 12 down-regulated miRNAs in carcinomas, as well as miRNAs differentially expressed in ER (11 miRNAs) and PR (7 miRNAs) positive specimens. Follow-up studies have validated some of these miRNAs (40) , suggested >30 miRNAs differentiating tumor subtypes (41, 42) , and defined the cell-type-specific localization of a few of these miRNAs (43) . Our sequencing approach using a large number of samples, including various disease subtypes, stages and cell line models allowed us to evaluate miRNA deregulation in the context of miRNA abundance, sequence variation and tissue heterogeneity, important elements in identifying miRNAs that would be useful prognostic and diagnostic markers, or prioritizing miRNAs for further studies.
Do miRNAs hold potential as diagnostic and prognostic markers in breast cancer?
When comparing miRNA levels between normal breast and carcinomas we identified 10 abundant miRNA sequence families (>1% rf) showing 3-to 12-fold changes. We noted up-regulation of sf-miR-21(1) and down-regulation of cluster-mir-98(13) members, sfmiR-22(1), sf-miR-145(1), sf-miR-378(1), sf-miR-497(1), sf-miR-320(1), sf-miR-451(1), as well as up-regulation of sf-miR-142-3p not previously reported. Sf-miR-145(1), sf-miR-451(1) and sf-miR-142-3p were absent from tumor cell lines, likely reflecting changes in tissue composition. sf-miR-19a(3) demonstrated approximately three-fold higher levels in TNBCs, a modest change that would not easily meet the requirements for a robust diagnostic marker. Most of the statistically significant changes in miRNA levels between tumor types involve low abundant miRNAs that are challenging to detect (see below). Moreover, when comparing the potential of overall miRNA profiles to differentiate tumor types to the potential of mRNAs profiles, miRNAs did not further clarify the assignment. Both miRNA and mRNA profiles are confounded by tissue heterogeneity, and given that miRNAs demonstrate lineage specific expression, they may be more sensitive to changes in tissue composition. In the two large patient studies (>100 patients) only miR-210 was shown to be inversely correlated to time to metastasis, disease free and overall survival (28, 29) . Foekens et al. focused on ER positive lymph node negative breast tumors, but also extended their findings to TNBC, while Camps et al. focused on ER positive patients. Our study showed higher levels of miR-210 in invasive compared to non-invasive carcinomas, but did not confirm a significant prognostic role. Other studies investigating miRNAs in breast cancer metastasis are based on cell line and animal models, are validated with smaller (~20) patient sample collections (15, 26, 27, 16) . The differences in miRNA levels in patients that went on to develop metastases involve lowly abundant miRNAs, which are challenging to translate into prognostic markers given the limits of detection of the currently available experimental methods. However, improvements in assay sensitivity, as well as detection of miRNAs in the serum allowing earlier detection or surveillance of abundant tumor specific miRNAs during therapy, promise use of miRNAs as biomarkers. By comparing ductal cell lines with ductal tumor specimens we identified miRNAs that were expressed in ductal cells or other cell types, such as hematopoetic cells or adipocytes. Changes in miRNA levels reflect either their up-or down-regulation in ductal cells and likely 148 9 miRNA sequence and expression analysis in breast tumors signify associated tumor-cell oncogenic pathways, or changes in tissue composition, i.e. presence of lymphocytic infiltrate or necrosis. Given this lineage specificity, miRNA levels may allow estimation of other cell types present in a heterogeneous biopsy sample to normalize molecular array based diagnostic tests.
Understanding miRNA involvement in oncogenic processes.
Viewing miRNAs in the context of their abundance defined miRNAs whose levels suggest regulatory functions, with 1% rf roughly equivalent to 1,500 copies per cell. miRNA nucleotide variations are being implicated in tumorigenesis; however, evidence for their significance is limited (44) . In our study, nucleotide variations were not identified in the regulatory regions of abundant miRNAs. Most significant changes in miRNA levels between tumor types involved low abundant miRNAs, challenging a role for these miRNAs in the HER2-and ER-related oncogenic pathways. The tumor subtype most distinct based on miRNAs was TNBC, suggesting miRNA regulation by oncogenic cluster-mir-17(12) members. It is, however, important to note that low abundant miRNAs could be highly expressed in a subpopulation of cells responsible for tumor invasion. Moreover, lower abundant miRNAs, even if not related to oncogenic events, may strengthen predictive capabilities of other mRNA or epigenetic-based markers. We noted the drastic up-regulation of miR-21 in carcinomas, recently identified as an oncogene in mouse models (45, 46) . We showed that miRNA levels were comparable in normal breast and tumors, suggesting that the down-regulation of other abundant miRNAs in tumors could be a consequence of competition for processing by the RNAi machinery. Upregulation of miR-21 may drive tumorigenesis both through a direct effect on targets involved in repressor functions, as well as down-regulation of tumor suppressor miRNAs, such as members of the cluster-mir-98(13). In conclusion, our abundance-based view of miRNA expression in breast cancer supports a focus on oncogenic miR-21, which is specifically upregulated in carcinomas, and miR-21 targets with potential tumor suppressor functions, as promising therapeutic targets. Given that miR-21 is up-regulated in many other malignancies, identifying the tumorigenic pathways it regulates has broad implications in oncology. Table S1 . Clinical follow-up data were available for 48 TNBC and 49 HER2 positive patients. Therapy for these patients consisted of breast conserving surgery or modified radical mastectomy, with or without adjuvant therapy. Adjuvant therapy consisted of radiation therapy, hormonal therapy or chemotherapy. 22 out of 49 HER2 positive and 28 out of 48 TNBC patients received anthracycline-based, cyclophosphamide, methotrexate and fluorouracil chemotherapy, hormonal treatment or a combination modality. Patients were excluded from the survival analyses if they had a history of prior malignancy, preoperative systemic therapy, or special histological type. The MCF7, HCC38, MCF10A and BT-474 cell lines were purchased from ATCC. ZR-751 was a gift from John Hilkens and MDA-MB134 from Marleen Kok.
RNA isolation
Fresh-frozen (frozen immediately after surgery and stored at -80°C) normal and tumor tissue was collected. RNA was isolated from approximately thirty 30-µm cryosections corresponding to approximately 20 mg of tissue, using the first and last section to assess tumor content; only samples containing more than 50% tumor were further characterized. The tissues were homogenized in Trizol using a Polytron instrument (polytron ® , PT, MR2100, Kinematica AG, Luzern) for 1 min and total RNA was isolated as described in Landgraf et. al (22) . Quality of isolated RNA was assessed on a 1% agarose gel based on the relative abundance of the 18S and 28S subunits of ribosomal RNA.
Small RNA sequencing and bioinformatics analysis
We used a barcoding small RNA sequencing approach (30) . We employed 21 different barcodes obtaining 1.8-26.5 mio reads per sequence run (18-87% reads with extractable barcodes) (Suppl. Table S2A ). We selected reads with an insert of 16-25 nt. Adapter sequences were extracted from sequence reads, using the following parameters: 4-nt minimum overlap of 3' adapter, or 5-nt minimum 3' overlap of adapter with one mismatch excluding insertions and deletions in the first nucleotide of the adapter past the barcode; barcodes were assigned without allowing any mismatches. On average 80% of the extracted reads represented prototypical miRNAs (based on our annotation database), 0.005% viral miRNAs and 0.2% piRNAs (based on NCBI definitions). Setting a threshold of > 10 reads per miRNA for the pool of all 49,479,978 miRNA sequence reads (179 patient samples and 6 cell lines), we identified a total of 888 prototypical mature and miRNA star sequences (representing the two strands obtained after miRNA precursor processing). Resetting the threshold to 5,000 reads, we identified 231 miRNA and miRNA star species together constituting 99% of all miRNA reads. To assess if experimental variables affected miRNA profiles, we profiled 54 samples in replicate and performed Spearman correlation yielding a median correlation coefficient of 0.92 using the top expressed miRNAs (represented with >5,000 sequence reads across all samples) (Suppl . Table S7 ). miRNA genomic clusters were defined taking into consideration EST evidence and levels of miRNA expression from our data (22) . Typically, the greatest genomic distance between miRNAs was 5 kb. Sequence families were defined based on seed sequence similarity (position 2-8) allowing only one transition in these positions, as well as 3' end similarity (position 9 through 3' end) allowing up to 50% mismatches with additional manual curation (Suppl . Table S4 ).
Northern Blot analysis 5 μg of total RNA was used for Northern blot analysis as previously described (22) . Briefly, equal loading of the lanes was confirmed by ethidium bromide staining of the tRNA band. Synthetic standards containing 2, 10 and 50 fmol oligodeoxynucleotide corresponding to each miRNA were run on each gel and used as references to quantify miRNA expression. After each experiment, blots were stripped in water, 0.1% SSC at 85 °C for 5 min, were re-probed up to 4 times, the final time for U6 snRNA as control for loading and degradation. The spot intensities (photo-stimulated luminescence) were quantified using ImageGauge software in units of photo-stimulated luminescence (PSL) and corrected for background intensity.
Statistical analysis
Kaplan-Meier analysis was conducted for the top 5 significantly desregulated miRNAs (p<0.001 to account for multiple testing correction for 20 comparisons) between patients that presented with metastasis as first event. For each miRNA tested, the patients were split into two groups at the median. Difference between the two Kaplan-Meier curves was assessed with the Log-Rank test.
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151 9 miRNA sequence and expression analysis in breast tumors Supplementary Figure S1 : A. mRNA expression of genes encoding miRNA pathway components and genes implicated in miRNA biogenesis. We only used high quality probes and displayed the probe closest to the 3' UTR. Color histogram represents log2 expression. B. Quantitative Western blot of cell lysates from MCF7, HCC38 and BT474 cell lines using 60 mg of total protein, along with varying amounts of 6X-His-tagged recombinant purified EIF2C2, probed for the EIF2C2 antibody described in Landthaler et. al (49) . Two panels shown are derived from the same blot (lanes removed included samples not of relevance to this study). 
